Markets
BAX

Baxter Announces FDA Approval Of Clinimix And Clinimix E Injections

(RTTNews) - Baxter International Inc. (BAX) announced the U.S. FDA approval of new formulations of Clinimix Injections and Clinimix E Injections with higher protein for patients requiring parenteral nutrition. These new Clinimix formulations contain up to 80 g/L of amino acids, the highest protein in any multi-chamber bag available in the U.S.

"The introduction of Clinimix and Clinimix E formulations offers the highest protein in a multi-chamber bag in the U.S., allowing clinicians more flexibility in meeting their patients' nutritional goals," said Heather Knight, general manager of Baxter's U.S. hospital products business.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BAX

Latest Markets Videos

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More